Skip to main content

Advertisement

Table 2 Serious adverse events

From: Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis

Study No. of patients No. of patients/events with SAE Description of SAE (comments from investigator)
Beinhardt (2016) [27] 10 5 (5/5 on dialysis) 1 pt.: recurring peritonitis
1 pt.: renal anemia
1 pt.: graft failure after orthotopic liver transplantation (LOT)
1 pt.: cirrhosis due to HCV recurrence after OLT
1 PT: pneumonia
Goel (2018) [23] 41 2 (0/2 on dialysis) 1 pt.: acute mild pancreatitis after renal transplantation
1 pt.: worsening of ascites
Lawitz (2017) [33] 18 4 (0/4 on dialysis) 1 pt.: acute kidney injury and noncardiac chest pain
1 pt.: dehydration and hypotension
1 pt.: acute renal failure
1 pt.: hypotension and synocope (no SAEs were considered related to study drug)
Saxena (2015) [47] 18 3 NA
Cox-North (2017) [35] 29 1 (1/1 on dialysis) 1 pt.: cardiac event (unable to draw any conclusions about the safety of SOF regimens in those with underlying cardiac disease)